Menu Search
Equities

Legend Biotech Corp

9LB:MUN

Legend Biotech Corp

Actions
  • Price (EUR)37.80
  • Today's Change0.000 / 0.00%
  • Shares traded1.00
  • 1 Year change-37.52%
  • Beta--
Data delayed at least 15 minutes, as of Nov 13 2024 07:04 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Legend Biotech Corp had net income fall 16.11% from a loss of 446.35m to a larger loss of 518.25m despite a 143.70% increase in revenues from 117.01m to 285.14m.
Gross margin60.28%
Net profit margin-62.50%
Operating margin-81.89%
Return on assets-15.29%
Return on equity-22.21%
Return on investment-17.63%
More ▼

Cash flow in USDView more

In 2023, Legend Biotech Corp increased its cash reserves by 62.55%, or 491.68m. Cash Flow from Financing totalled 791.49m or 277.58% of revenues. In addition the company used 393.28m for operations while cash from investing totalled 92.79m.
Cash flow per share-1.45
Price/Cash flow per share--
Book value per share6.33
Tangible book value per share6.31
More ▼

Balance sheet in USDView more

Legend Biotech Corp appears to have a strong balance sheet and has grown its cash reserves consistently over the last four years to total 1.28bn.
Current ratio4.84
Quick ratio4.78
Total debt/total equity0.2924
Total debt/total capital0.2263
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.